According to a recently published report by Brisk Insights, the Global Glioblastoma Multiforme Market is expected to grow at the CAGR of 10.9% during 2017-2025. The global glioblastoma multiforme market is segmented on the basis of drugs and geography. The report on global glioblastoma multiforme market forecast 2017-2025 (by drugs, and geography) provides a detailed overview and predictive analysis of the market.

Full report available on Glioblastoma Multiforme Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/glioblastoma-multiforme-market

Market Insights

Glioblastoma multiforme (GBM) is the most common and most malignant of the glial tumors. It is the most common brain tumor in adults and also the most antagonistic form of brain tumor. U.S. National Cancer Institute states that Glioblastoma multiforme accounts for almost 15.4% of all primary brain tumors and about 60%-75% of all astrocytoma. Moreover, as per the World Health Organization (WHO), the incidence rate of GBM is 2 to 3 per 100,000 people in the U.S. and Europe. By type of drugs, the glioblastoma multiforme market was dominated by temozolomide due to delayed progression of temozlomide without impacting the quality of life and lower side effects as compared to other molecules. Moreover, the combination of radiotherapy and temozolomide chemotherapy is suggested by many medical practitioners as a standard treatment for glioblastoma multiforme. In terms of geography, North America and Europe dominated the global glioblastoma multiforme market. The critical success factors supporting the growth of glioblastoma multiforme market in these regions include growing government initiatives and private organizations to increase public awareness related to diagnosis and treatment of glioblastoma multiforme and advanced healthcare infrastructure to boost the pipeline research in this market. Asia-Pacific is expected to grow at a significant rate where with Japan, China and India leading the glioblastoma multiforme market respectively.

Scope of the report

1. Global Glioblastoma multiforme Market, by Drug, 2015–2025 ($ Million)

1.1. Temozolomide
1.2. Bevacizumab
1.3. Carmustine
1.4. Pipeline Analysis (Projected sales of Phase III Drugs estimated till 2022 ($ Million)

2. Global Glioblastoma multiforme Market, by Geography, 2015-2025 ($ Million)

2.1. North America 
2.2. Europe 
2.3. Asia Pacific 
2.4. Latin America (LATAM)                                
2.5. Middle East and Africa (MEA)

3. Profiles

3.1. AbbVie, Inc.
3.2. Activartis GmbH
3.3. Agenus Inc. 
3.4. Arog Pharmaceuticals, Inc.  
3.5. Bristol-Myers Squibb Company
3.6. Cavion LLC
3.7. Celldex Therapeutics, Inc.
3.8. CTI BioPharma Corporation (Formerly Cell Therapeutics Inc.)
3.9. Cortice Biosciences Inc. 
3.10. Eisai Co., Ltd.
3.11. F. Hoffmann-La Roche Ltd.
3.12. Exelixis Inc.
3.13. Peregrine Pharmaceuticals, Inc.
3.14. Others

Request Sample: http://www.briskinsights.com/sample-request/355

About Us

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to  aid businesses identify market opportunities optimize strategies. Our team of 200 analysts’ provides enterprises with strategic insights. Brisk Insights works to help enterprises grow through strategic insights and actionable solutions

Contact Us: 

Office 1094

109 Vernon House

Friar Lane

Nottingham

NG1 6DQ

+448081890034 (UK)

sales@briskinsights.com